(Reuters) – GSK, on Monday, announced an exclusive partnership with China’s Chongqing Zhifei Biological Products (Zhifei) for its shingles vaccine.
Zhifei will purchase worth 2.5 billion pounds ($3.05 billion) of the vaccine, named ‘Shingrix’, over an initial three-year period, GSK said. ($1 = 0.8193 pounds)
(Reporting by Eva Mathews in Bengaluru; Editing by Savio D’Souza)
